Literature DB >> 11442359

Hypocretin levels in sporadic and familial cases of canine narcolepsy.

B Ripley1, N Fujiki, M Okura, E Mignot, S Nishino.   

Abstract

Familial and sporadic forms of narcolepsy exist in both humans and canines. Mutations in the hypocretin receptor 2 gene (Hcrtr 2) cause canine familial narcolepsy. In humans, mutations in hypocretin-related genes are rare, but cerebrospinal fluid (CSF) hypocretin-1 is undetectable in most sporadic cases. Using the canine model, we investigated ( 1 ) whether hypocretin deficiency is involved in sporadic cases and ( 2 ) whether alterations in hypocretin neurons or ligand levels also contribute to the phenotype in Hcrtr 2 mutants. We found that hypocretins were undetectable in the brains of three of three and the CSF of two of two sporadic narcoleptic dogs tested. In contrast, hypocretin levels were not altered in brains and CSF of genetically narcoleptic Dobermans, and hypocretin-containing neurons were of normal appearance. Therefore, multiple hypocretin-related etiologies are likely to be involved in canine narcolepsy. The presence of hypocretin peptides in Hcrtr 2-mutated animals suggests that neurotransmission through Hcrtr 1 may be intact, arguing for a preferential importance of Hcrtr 2-mediated function in narcolepsy. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11442359     DOI: 10.1006/nbdi.2001.0389

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  25 in total

1.  [The neurotransmitter, hypocretin. An overview].

Authors:  C Baumann; C Bassetti
Journal:  Nervenarzt       Date:  2004-04       Impact factor: 1.214

Review 2.  Narcolepsy: immunological aspects.

Authors:  Sebastiaan Overeem; John Logan Black; Gert Jan Lammers
Journal:  Sleep Med Rev       Date:  2008-03-04       Impact factor: 11.609

Review 3.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

Review 4.  Hypocretin ligand deficiency in narcolepsy: recent basic and clinical insights.

Authors:  Cayde Ritchie; Masashi Okuro; Takashi Kanbayashi; Seiji Nishino
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

5.  Orexin neurons suppress narcolepsy via 2 distinct efferent pathways.

Authors:  Emi Hasegawa; Masashi Yanagisawa; Takeshi Sakurai; Michihiro Mieda
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

Review 6.  [Moebius syndrome and narcolepsy].

Authors:  S Krämer; U Goldammer; E Sindern
Journal:  Nervenarzt       Date:  2014-12       Impact factor: 1.214

7.  Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls.

Authors:  Seiji Nishino; Eiko Sakurai; Sona Nevsimalova; Yasushi Yoshida; Takehiko Watanabe; Kazuhiko Yanai; Emmanuel Mignot
Journal:  Sleep       Date:  2009-02       Impact factor: 5.849

Review 8.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

9.  Melanin-concentrating hormone neurons contribute to dysregulation of rapid eye movement sleep in narcolepsy.

Authors:  Fumito Naganuma; Sathyajit S Bandaru; Gianna Absi; Carrie E Mahoney; Thomas E Scammell; Ramalingam Vetrivelan
Journal:  Neurobiol Dis       Date:  2018-08-24       Impact factor: 5.996

10.  Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Simon P Fisher; Tsui-Ming Chen; Deepti R Warrier; Thomas S Kilduff
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.